{"version":"1.0","type":"link","title":"Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.","author_name":"You C 외","author_url":"https://prs-insight.online/author/You%20C","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/124356","thumbnail_width":1200,"thumbnail_height":630}